1. ZOHé: A Prospective Study of the Use of Biosimilar Filgrastim Zarzio in Clinical Practice in Patients Treated With Chemotherapy for Lymphoid Malignancies 
Gandhi Laurent Damaj, Omar Benbrahim, Maya Hacini, Inna Voronina, Khaled Benabed, Ravaka-Fatoma Soumoudronga, Isabelle Gasnereau, Corinne Haioun, Philippe Solal-Céligny 
Clinical Lymphoma, Myeloma and Leukemia 
Volume 17, Issue 6, Pages e2 (June 2017)
DOI: /j.clml
Copyright © 2017 The Authors Terms and Conditions

2. Figure 1
Description of Severe Neutropenia Episodes During Study Follow-Up, by Subgroup (n = 175)
Abbreviations: HL = Hodgkin lymphoma; HM = hematological malignancies; NHL = non-Hodgkin lymphoma.
Clinical Lymphoma, Myeloma and Leukemia  , e2DOI: ( /j.clml )
Copyright © 2017 The Authors Terms and Conditions

3. Supplemental Figure 1
Study Population for the HM Cohort. ∗Four Patients Were Excluded From the Analysis: 2 Due to Deviation From the Eligibility Criteria and 2 Were Duplicated Patient Records. †The 18 Patients Who Left the Study Prematurely and Were Not Followed Up Were Comparable to the Followed-Up Patients in Terms of Age, Sex, Comorbidities Concomitant With Neutropenia Risk, and Number of Chemotherapy Cycles Planned. There Were More Patients With Prior Episodes of Neutropenia (P = .04) and Patients Had a Lower Performance Score (P < .01) at Inclusion Compared With the Followed-Up Patients. ‡Sixty-Three of These Patients Left the Study Before the 3-Month Follow-Up Visit but Were Reviewed for Data Collection
Abbreviation: HM = hematological malignancies.
Clinical Lymphoma, Myeloma and Leukemia  , e2DOI: ( /j.clml )
Copyright © 2017 The Authors Terms and Conditions